PTC announces submission of sepiapterin MAA for treatment of PKU to EMA

PTC Therapeutics

28 March 2024 - First marketing authorisation submission for sepiapterin with additional global submissions to follow in 2024.

PTC Therapeutics announced today the submission of the sepiapterin MAA to the EMA.

Read PTC Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , Dossier